Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
The company will focus on what it called a previously unexplored field in drug discovery, membrane-less cell organelles called biomolecular condensates
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
System1 Biosciences' platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
The San Diego-based firm plans to integrate its "No Cell Left Behind" platform with electronic medical records and big data analytics.
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.